Monopar Therapeutics Inc.
MNPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $582 | $250 | $251 | $834 |
| - Cash | $127,677 | $40 | $40 | $46 |
| + Debt | $71 | $0 | $0 | $0 |
| Enterprise Value | -$127,025 | $211 | $212 | $788 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$2 | -$3 | -$11 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$2 | -$3 | -$11 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.48 | -0.35 | -0.38 | -0.95 |
| % Growth | -37.1% | 7.9% | 60% | – |
| Operating Cash Flow | -$2 | -$1 | -$6 | -$2 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$2 | -$1 | -$6 | -$2 |